Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genmab A/S ADR (NQ: GMAB )

24.33 +0.21 (+0.87%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 483,996
Open 24.27
Bid (Size) 24.20 (2)
Ask (Size) 24.48 (4)
Prev. Close 24.12
Today's Range 24.23 - 24.43
52wk Range 23.80 - 35.88
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Jin Medical International, Nio And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
NASDAQ:GMAB is probably undervalued for the fundamentals it is displaying.
GENMAB A/S -SP ADR (NASDAQ:GMAB) is an undervalued gem with solid fundamentals. 
Via Chartmill

Performance

YTD
-24.23%
-24.23%
1 Month
-12.17%
-12.17%
3 Month
-3.18%
-3.18%
6 Month
-19.62%
-19.62%
1 Year
-31.14%
-31.14%

More News

Read More
Don't overlook NASDAQ:GMAB—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
From Genmab A/S
Via Business Wire
Expert Ratings For Genmab
Via Benzinga
NASDAQ:GMAB: a strong growth stock preparing for the next leg up?.
Via Chartmill
NASDAQ:GMAB is showing good growth, while it is not too expensive.
Via Chartmill
Decoding 10 Analyst Evaluations For Genmab
Via Benzinga
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
Genmab Announces Changes to its Executive Committee
From Genmab A/S
Via Business Wire
On Holding Reports Mixed Q2 Results, Joins Tencent Music Entertainment And Other Big Stocks Moving Lower In Tuesday Pre-Market Session
Via Benzinga
Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock?
Via Chartmill
What 8 Analyst Ratings Have To Say About Genmab
Via Benzinga
GMAB Stock Earnings: Genmab Misses EPS, Beats Revenue for Q2 2024
Via InvestorPlace
BioNTech's Q2 Loss Widens Amid Low Demand For Its Pfizer-Partnered COVID-19 Vaccine, Increases R&D Spending On New Cancer Products
Via Benzinga
Exposures COVID-19
While growth is established for NASDAQ:GMAB, the stock's valuation remains reasonable.
Via Chartmill
What 8 Analyst Ratings Have To Say About Genmab
Via Benzinga
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
Via Chartmill
NASDAQ:GMAB, an undervalued stock with good fundamentals.
Via Chartmill
10 Analysts Assess Genmab: What You Need To Know
Via Benzinga
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway
Via Benzinga
Exposures Product Safety
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
7 Biotech Stocks to Buy on the Dip: June 2024
Via InvestorPlace
Despite its growth, NASDAQ:GMAB remains within the realm of affordability.
Via Chartmill
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.